Novo Nordisk on Wednesday forecast another year of double-digit growth as the Danish drugmaker began boosting U.S. supplies of its popular weight-loss drug Wegovy and pledged to roll out in new markets amid competition from Eli Lilly.

Danish insulin maker Novo Nordisk A/SNVO,-1.50%has signed a memorandum of understanding with the Food and Drug Administration of Iran to build a new manufacturing facility in the country. The EUR70 million plant will manufacture Novo Nordisk's FlexPen prefilled devices and the project is expected to last five years. "It signals our long-term ...